Titan Biotech Limited (524717) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Titan Biotech Limited ₹622, price ₹392, upside +58.8%, quality 73 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Titan Biotech Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹38.96 – ₹529.20 · fair‑value band ₹328.89 – ₹814.85 · the ₹391.50 price screens below the ₹621.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Titan Biotech in your weekly email
Every Wednesday you see whether Titan Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Titan Biotech Limited manufactures and sells biological products in India.
Show more
Titan Biotech Limited manufactures and sells biological products in India. The company offers food ingredients, including hydrolyzed vegetable protein, yeast extract powder, calcium propionate powder, potassium sorbate, and calcium lactate; collagen and protein products, such as specter whey protein, collagen peptides, brown rice protein, fish collagen, pea protein isolate, chicken protein isolate, soya protein isolate, milk protein, and protein hydrolysate; and nutraceutical and pharmaceutical products comprising sodium caseinate, chondroitin sulfate, hyaluronic acid, methyl sulphonyl methane, chelated minerals, peptone, OX bile extract, cholic acid, cerebroprotein hydrolysate, methyl sulphonyl methane, iron protein succinylate, medicinal yeast, and brewer yeast protein, as well as liver, meat, malt, and yeast extracts. In addition, it provides products in the areas of animal nutrition, including binding agents, chelates minerals, mold inhibitors, proteins, and yeasts. The company's products are used in the field of pharmaceuticals, nutraceuticals, food and beverages, biotechnology and fermentation, cosmetics, veterinary and animal feed, agriculture, microbiology culture media, plant tissue culture media, etc. The company also exports its products. Titan Biotech Limited was incorporated in 1992 and is based in New Delhi, India.
Stock analysis
Titan Biotech Limited (524717) currently trades at ₹391.50, while our model-based Fair Value estimate is ₹621.85, implying the stock looks roughly 37.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹862.08 per share, and 21 of the 26 models we run sit above the ₹391.50 price.
Bear case: the Asset-Based group reads lowest at ₹147.19, and 5 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹328.89 (bear) to ₹814.85 (bull), the price of ₹391.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Health Care sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Titan Biotech Limited reported revenue of ₹2.1B in FY2026 versus ₹1.2B in FY2022, a compound +13.7%/yr. Reported net income was ₹299M in FY2026, compounding +8.3%/yr from FY2022.
Key figures
Market cap ₹1.5B (≈ $15.3M) · P/E ratio 4.7 · P/S ratio 0.67 · EPS (TTM) ₹28.60 · Dividend yield 0.8% · Net margin 14.5% · Return on equity 49.5% · Return on assets (EBIT) 18.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 117% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at 10% fair-value upside, at 59%, 524717 screens cheaper than that median.
Fair Value models
Bear ₹328.89Fair Value ₹621.85Bull ₹814.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹14.07 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+31.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Start year 2021 (pandemic). Over 10 years: +16.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−21.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−22.7%
Dividend (yield on the price)0.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−22.7% vs 9.9%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → 16%
Start year 2021 (pandemic)
⚠ Revenue per share shrinking 8.5%/yr over ~7Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+40.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +34.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 623 stocks
Beats the industry median on 9/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside−46.4% · Above median
Profitability
Return on equity (TTM)49.5% · Top 25%
Return on assets25.2% · Top 25%
Net margin (TTM)21.3% · Top 25%
Operating margin (TTM)30.3% · Top 25%
Growth and dividend
Revenue growth76.5% · Top 25%
Dividend yield (TTM)0.8% · Below median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Titan Biotech Limited (524717) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹621.85 versus a price of ₹391.50, about +59% upside (undervalued).
What is the fair value of 524717?
Our model-based fair value for Titan Biotech Limited is ₹621.85 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹391.50.
What is the quality score of 524717?
Titan Biotech Limited has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Titan Biotech Limited (524717)?
Our model-based price target is the fair value of ₹621.85 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹328.89, optimistic scenario ₹814.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Titan Biotech Limited stock forecast for 2026?
Our models put fair value at ₹621.85, about +59% upside versus a price of ₹391.50 (undervalued). Cautious scenario ₹328.89, optimistic scenario ₹814.85. The calculation is refreshed regularly with new filings.
What is the revenue of Titan Biotech Limited (524717)?
Titan Biotech Limited reported trailing-twelve-month revenue of about ₹1.1B (latest available figure, as of Sep 24, 2026).
Does Titan Biotech Limited pay a dividend?
Titan Biotech Limited currently shows a dividend yield of about 0.79% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Titan Biotech Limited (524717)?
For today's price to be fair in a discounted-cash-flow model, Titan Biotech Limited would have to grow free cash flow by +40.3 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 524717 use?
Our models discount Titan Biotech Limited at 11.2 %: a base by market capitalisation (nano), damped by beta 0.64, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Titan Biotech Limited that is +40.3 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Titan Biotech Limited (524717) delivered so far?
Over the past 5 years revenue at Titan Biotech Limited grew +7.7 % a year. The price currently implies +40.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Titan Biotech Limited (524717) growing?
The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Titan Biotech Limited (+40.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Titan Biotech Limited (524717)?
The free-cash-flow yield on the price is 1.30 %: that much free cash flow Titan Biotech Limited produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Titan Biotech Limited (524717)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Titan Biotech Limited it is ₹621.85 per share (as of Sep 24, 2026), against a price of ₹391.50. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Titan Biotech Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 524717 trades below its calculated fair value: price ₹391.50, fair value ₹621.85, a gap of about +59% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 524717?
No. The price is what the market pays today (₹391.50); the fair value is what the company's own numbers justify (₹621.85). For Titan Biotech Limited the two are ₹230.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Titan Biotech Limited worth?
The market values Titan Biotech Limited at about ₹1.5B (market capitalisation, as of Sep 24, 2026). Per share that is ₹391.50; our models calculate a fair value of ₹621.85 per share.
What do the bullish and bearish scenarios say about 524717?
Our models span a range for Titan Biotech Limited: cautious scenario ₹328.89, base ₹621.85, optimistic ₹814.85 per share (as of Sep 24, 2026, price ₹391.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 524717?
Titan Biotech Limited trades at a price-to-earnings ratio of 4.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹621.85 is built from several models across several years.
How solid is the balance sheet of Titan Biotech Limited (524717)?
Balance-sheet figures for Titan Biotech Limited (as of Sep 24, 2026): return on equity 49.5%, debt of 0.00 per unit of equity. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is 524717 from its 52-week high?
Titan Biotech Limited trades at ₹391.50, about 26% below its 52-week high of ₹529.20 and 117% above the low of ₹180.32 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹621.85 is for.
Which stocks are comparable to Titan Biotech Limited?
From the same area (Health Care) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Titan Biotech Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹391.50, calculated fair value ₹621.85 (+59%), Quality Score 73/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 524717 calculated?
We run Titan Biotech Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹621.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Titan Biotech Limited currently trades 37 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Titan Biotech Limited (524717)?
The closing price on Oct 1, 2026 was ₹391.50. Our model-based fair value is ₹621.85, about +59% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Titan Biotech Limited right now?
The rarer combination: high quality (73/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range (₹328.89 to ₹814.85) leaves room in how you read the outcome.
Key figures of Titan Biotech Limited
How large is the market capitalisation of Titan Biotech Limited (524717)?
The market capitalisation of Titan Biotech Limited is ₹1.5B (≈ $15.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Titan Biotech Limited (524717)?
The price-to-sales ratio of Titan Biotech Limited is 0.67 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Titan Biotech Limited (524717)?
Earnings per share at Titan Biotech Limited are ₹28.60 (price ÷ EPS = P/E 4.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Titan Biotech Limited (524717)?
The dividend yield of Titan Biotech Limited is 0.8% (payout 10.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Titan Biotech Limited (524717)?
The net margin of Titan Biotech Limited is 14.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Titan Biotech Limited (524717)?
The return on equity (ROE) of Titan Biotech Limited is 49.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Titan Biotech Limited (524717)?
On an EBIT basis the return on assets of Titan Biotech Limited is 18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Titan Biotech Limited (524717)?
The operating margin of Titan Biotech Limited is 30.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Titan Biotech Limited (524717)?
Revenue at Titan Biotech Limited is growing +76.5% versus a year earlier (3y avg +12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Titan Biotech Limited (524717)?
Earnings per share at Titan Biotech Limited are growing +407% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Titan Biotech Limited (524717) carry?
The net debt of Titan Biotech Limited is ₹21.9M (fiscal year 2026, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Titan Biotech Limited in the live analysis
One click puts Titan Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
